Benzinga | Sep 21, 2020 10:01AM EDT

Misonix Reports Exclusive Supply, Distribution Deal With Gunze Limited For TheraGenesis Bilayer Wound Matrix

Misonix, Inc. (NASDAQ:MSON) ("Misonix") a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative tissue products that enhance clinical outcomes, announced today that it has entered into an exclusive supply and distribution agreement with Gunze Limited for TheraGenesis(r) Bilayer Wound Matrix. TheraGenesis is a proprietary, FDA cleared, porcine tendon derived collagen wound matrix with a silicone film layer used to treat trauma, burn and reconstructive wounds.



Stavros Vizirgianakis, Chief Executive Officer of Misonix, commented, "We are honored to have entered into a partnership with Gunze Limited and very much look forward to working together with their world-class team. The addition of TheraGenesis to our wound product portfolio, allows us to effectively compete in the U.S. xenograft skin substitute market. We have witnessed the success that Gunze Limited has achieved in marketing TheraGenesis outside the US under the brand name Pelnac(r), and we are confident that we will substantially build upon that success in the domestic market. The addition of TheraGenesis positions Misonix to compete effectively and gain market share in the traumatic, burn and reconstructive wound market, whereas TheraSkin(r), is our leading skin substitute to treat chronic wounds, and the recently added Therion(r) allows us to compete in the amniotic tissue market for both wound and surgical applications. We are the only company to offer the competitive advantage of state-of-the-art ultrasonic debridement with SonicOne(r) together with best-in-class skin substitutes to ensure optimal wound bed preparation resulting in better outcomes."

TheraGenesis is complimentary and expansive to Misonix's current tissue regeneration wound portfolio of TheraSkin and SonicOne, offering a strong competitive entry into the xenograft skin substitute segment of the over $1 billion U.S. skin substitute market and enables Misonix to leverage the growth opportunities in healing chronic wounds as well as in treating trauma and burn wounds.

Shinichiro Morita, Corporate Officer and General Manager of the Medical Division of Gunze Limited added, "Partnering with Misonix to bring TheraGenesis to the U.S. market is an exciting and positive development for Gunze. This alliance allows Gunze to expand its global footprint with a clinically proven skin substitute, Pelnac, while providing Misonix with an opportunity to synergistically expand their advanced wound care product portfolio. For the past 20 years, we have been providing innovative solutions for tissue engineering and regenerative medicine to medical professionals across over 35 countries, helping patients and health care providers achieve better clinical outcomes."